Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians’ views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology, 59(12), 3641–3649. Portico. https://doi.org/10.1002/ppul.27273

Rose, N. R., Chalamalla, A. R., Garcia, B. A., Krick, S., Bergeron, J., Sadeghi, H., Schellhase, D. E., Ryan, K. J., Dowell, A. E., Acosta, E. P., & Guimbellot, J. S. (2024). Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulmonary Pharmacology & Therapeutics, 86, 102301. https://doi.org/10.1016/j.pupt.2024.102301

Miller, J. E., Taylor‐Cousar, J. L., Overdevest, J. B., Khatiwada, A., Mace, J. C., Alt, J. A., Bodner, T. E., Chowdhury, N. I., DiMango, E. A., Eshaghian, P. H., Getz, A. E., Gudis, D. A., Han, E. J., Hwang, P. H., Keating, C. L., Khanwalkar, A., Kimple, A. J., Lee, J. T., Li, D., … Beswick, D. M. (2023). Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. International Forum of Allergy & Rhinology, 14(6), 1079–1087. Portico. https://doi.org/10.1002/alr.23312